title: [Plants, medicine and genetics, which applications for tomorrow?].
abstract: From 60,000 B.C. to the 19th century, plants were the main source for human drugs. Plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis at the beginning of the 19th century. However, 50% of small molecules used for cancer therapy or the most efficient drugs for flu or paludism treatment are still extracted or derived from plants. Furthermore, strategies which aim at improving plant expression systems for biopharmaceutical production are currently making them safe and extremely cost-effective alternatives to microbial and mammalian cell cultures for the production of either simple or highly complex recombinant therapeutic proteins.
authors.affiliation: CNRS, Université de Rouen, IFRMP23, UFR des Sciences, 76821 Mont Saint Aignan Cedex, France. lfaye@crihan.fr
authors.forename: Loïc
authors.initials: L
authors.lastname: Faye
authors.forename: Yves
authors.initials: Y
authors.lastname: Champey
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D000998:Antiviral Agents / Q000627:therapeutic use; D004926:Escherichia coli / Q000235:genetics; D030342:Genetic Diseases, Inborn / Q000188:drug therapy* / Q000235:genetics*; D005826:Genetics, Medical; D006801:Humans; D053139:Oseltamivir / Q000627:therapeutic use; D010946:Plants, Medicinal; D014612:Vaccines / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents; D014612:Vaccines; D053139:Oseltamivir